Researchers at the University of Copenhagen have developed a patch for easier and more effective treatment of psoriasis. The ...

Johnson & Johnson (NYSE: JNJ) has announced encouraging results from its Phase 3 investigational study of icotrokinra ...

Results for icotrokinra (JNJ-2113) have shown the drug’s potential to offer significant relief for patients suffering from moderate-to-severe plaque psorias ...

Johnson & Johnson has reported positive outcomes from its Phase III trial of oral icotrokinra for treating plaque psoriasis.

University of Copenhagen researchers have developed a prototype patch for treating plaque psoriasis, which may simplify ...

Researchers at the University of Copenhagen have developed an electrospun nanofibre patch for the easier and more effective ...

Researchers at the University of Copenhagen have developed a patch for easier and more effective treatment of psoriasis. The ...

Researchers conducted a nationwide cohort study using data from the Taiwan National Health Insurance database and the Taiwan ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily ...

Vista, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, today announced a strategic partnership with the National Psoriasis ...